Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Provectus BiopharmaceuticalsPVCT -4.00% 14-Day RSI is 48.36 as of Aug. 03, 2026. The stock has 3 warning signs investors should review. Among 1,422 Biotechnology companies, Provectus Biopharmaceuticals ranks worse than 67.65% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Provectus Biopharmaceuticals 14-Day RSI Related Terms
PVCT vs PSTV, ALGS, ATNM: 14-Day RSI Comparison
For the Biotechnology subindustry, Provectus Biopharmaceuticals's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Provectus Biopharmaceuticals 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Provectus Biopharmaceuticals's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Provectus Biopharmaceuticals (PVCT) has a 14-Day RSI of 48.36 as of Aug. 03, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Provectus Biopharmaceuticals and its competitors. According to the industry distribution chart, Provectus Biopharmaceuticals ranks #962 out of 1422 companies in the Biotechnology industry, placing it in the top 67.7%.
Is Provectus Biopharmaceuticals' 14-Day RSI too high?
Provectus Biopharmaceuticals' current 14-Day RSI is 48.36. The Biotechnology industry median 14-Day RSI is 44.07. Provectus Biopharmaceuticals' value of 48.36 is 9.7% above this industry median. Based on the distribution chart, Provectus Biopharmaceuticals ranks #962 out of 1422 companies in the Biotechnology industry, which is below the industry midpoint.
How does Provectus Biopharmaceuticals' 14-Day RSI compare to PSTV and ALGS?
According to the Biotechnology industry distribution chart, Provectus Biopharmaceuticals ranks #962 out of 1422 companies for 14-Day RSI. This places Provectus Biopharmaceuticals in the lower half of its industry. The industry median 14-Day RSI is 44.07. Provectus Biopharmaceuticals' value of 48.36 is 9.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 44.07, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Provectus Biopharmaceuticals's current 14-Day RSI of 48.36 is 9.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Provectus Biopharmaceuticals and its competitors. For the Biotechnology industry, the median 14-Day RSI is 44.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Provectus Biopharmaceuticals's current 14-Day RSI is 48.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Provectus Biopharmaceuticals stock overvalued right now?
Provectus Biopharmaceuticals (PVCT) has a current 14-Day RSI of 48.36. The current 14-Day RSI is 48.36 and 9.7% above the Biotechnology industry median of 44.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Provectus Biopharmaceuticals (PVCT), the current 14-Day RSI is 48.36 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of bioactive synthetic small molecule halogenated xanthenes (HXs). Its flagship HX molecule is named rose bengal sodium (RBS). The company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient (API) in all its clinical development and non-clinical research programs. It has one operating and reporting segment, namely, the development of immunotherapy medicines.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PVCT has been successfully added to your 
